NTT
17.5.2023 10:10:26 CEST | Business Wire | Press release
Aiming to implement terabit-class wireless transmission to support wireless demand in the 2030s, NTT Corporation (NTT) has successfully achieved the world’s first “orbital angular momentum (OAM) multiplexing high-capacity wireless transmission—at 1.44 Tbit/s—using an ultra-wide bandwidth of 32 GHz. As an innovative wireless-communication technology that uses the sub-terahertz (sub-THz) band, this achievement will enable wireless access to vast amounts of information at data-transfer rate exceeding 1 Tbit/s. This achievement was realized using the sub-THz band within the range from 135 GHz to 170 GHz, and is an innovative wireless communication technology that enables wireless access to a huge amount of information exceeding 1 Tbit/s. As a key element of the “Innovative Optical and Wireless Network” (IOWN), which we aim to implement with our global partners, it is an extension of the high-capacity communication network and information-processing infrastructure centered on light to wireless networks including 6G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006084/en/
Figure 1: Image of OAM-multiplexing transmission technology and trends in high-capacity wireless transmission (Graphic: Business Wire)
Aiming to support the high-capacity network and information processing infrastructure of the IOWN and 6G and prepare for the increasing future demand for wireless communications, NTT is engaged in research and development with the goal of achieving terabit-class wireless transmission. To enhance the capacity of wireless communications, NTT is increasing the spatial multiplexing order by applying on a new principle using radio waves with “orbital angular momentum” (Figure 1) to increase wireless-transmission capacity and using the sub-terahertz (sub-THz) band to increase transmission bandwidth.
The approach taken by NTT is to use an analog circuit called a “Butler matrix” to increase the spatial multiplexing order by multiplexing multiple OAM waves. This approach reduces the enormous amount of digital signal processing required to eliminate interference between multiplexed data streams in high-capacity communications exceeding one terabit.
In this research, NTT has promoted research and development of sub-THz-band waveguide technology and succeeded in developing an antenna-integrated Butler matrix that operates with a wide bandwidth and low loss. The antenna-integrated Butler matrix is designed to simultaneously generate and separate eight different OAM waves over a very wide bandwidth, i.e., 135 to 170 GHz, which can be used to multiplex and transmit eight data signals. Moreover, by performing OAM multiplexing transmission with two different polarizations, it is possible to multiplex and transmit twice as many data signals simultaneously without them interfering. We conducted transmission tests using the antenna-integrated Butler matrix, and we achieved the world’s first successful large-capacity wireless transmission totaling 1.44 Tbit/s in the sub-THz bands of 135.5 to 151.5 GHz and 152.5 to 168.5 GHz (Figure 2). This transmission capacity is equivalent to the speed of simultaneous transmission of approximately 35,000 ultra-high-definition 4K videos (at about 40 Mbit/s) that can be available on current video websites. This speed enables the simultaneous transmission of 140 or more uncompressed 4K videos (at about 10 Gbit/s) for applications that require ultra-low latency.
This technology is expected to enable (i) broadband and high-speed wireless transmission comparable to optical transmission systems and (ii) seamless connection between wireless and optical transmission systems without the need for a complex digital signal-processing system for spatial multiplexing, since the analog circuit (i.e., the Butler matrix) handles the multiplexing of OAM waves. The next step in this development is to conduct demonstrations over longer distances (exceeding 100 m) while envisioning various applications of this technology in the real world, including wireless backhaul/fronthaul between base stations and relay transmission (Figure 3). We expect the eventual development of this technology to support the creation and spread of various future services, such as VR/AR (virtual reality/augmented reality), high-definition video transmission, connected cars, and telemedicine, as innovative wireless-communication technology in the IOWN and 6G era.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006084/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
